Literature DB >> 23116753

Problems related to CMV infection and biliary atresia.

Samuel W Moore1, Caroline Zabiegaj-Zwick, Etienne Nel.   

Abstract

BACKGROUND: Human cytomegalovirus (CMV) infection is related to biliary disease, being cholestatic in its own right. It has also been associated with intrahepatic bile duct destruction and duct paucity, indicating a possible role in extrahepatic biliary atresia pathogenesis and progression. When related to biliary atresia CMV IGM positive patients appear to have more liver damage thus affecting outcome. Methods We carried out a retrospective chart review on 74 patients diagnosed with hepatobiliary disease (2000-2011).
METHODS: included clinical and outcome review as well as evaluation of potential risk factors. Patients were divided into 2 groups those with biliary atresia and those without Biliary atresia (BA). The 2 groups were compared in terms of CMV infection.
RESULTS: Of the 74 patients with hepatobiliary disease investigated, 39 (52%) were shown to have Biliary atresia and 35 other cases. 12 of the BA group and 4 of the non-BA were excluded due to lack of data Twenty-seven (69%) of the biliary atresia group had sufficient available data for review. Of these, 21 (78% of the 27) had CMV positivity (IgM/IgG) on testing, with 20 of these being IgM positive versus 8 in the non-biliary atresia group. (p<0.01) Two (7.5%) of 27 BA infants were HIV exposed being born to HIV positive mothers whereas HIV positivity was observed in 7 (35%) of the non-biliary atresia group (p<0.01). Both of these biliary atresia infants were CMV IgM positive. Long- term outcome of the 21 with CMV positivity showed 3 deaths (non-HIV exposed) and a higher rate of severe early liver damage suggesting a poorer outcome in CMV affected patients.
CONCLUSIONS: This study suggests a correlation between CMV exposure, infection and surgical hepatobiliary disease including biliary atresia affecting outcome.HIV positivity does not preclude Biliary atresia and should be further investigated.

Entities:  

Mesh:

Year:  2012        PMID: 23116753     DOI: 10.7196/samj.6163

Source DB:  PubMed          Journal:  S Afr Med J


  6 in total

Review 1.  Early and Peri-operative Prognostic Indicators in Infants Undergoing Hepatic Portoenterostomy for Biliary Atresia: a Review.

Authors:  Robert N Lopez; Chee Y Ooi; Usha Krishnan
Journal:  Curr Gastroenterol Rep       Date:  2017-04

2.  Identification of the plasma metabolomics as early diagnostic markers between biliary atresia and neonatal hepatitis syndrome.

Authors:  Dongying Zhao; Lianshu Han; Zhengjuan He; Jun Zhang; Yongjun Zhang
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

3.  Characteristics and prognosis of hepatic cytomegalovirus infection in children: 10 years of experience at a university hospital in Korea.

Authors:  Chae-Yeon Min; Joo Young Song; Su Jin Jeong
Journal:  Korean J Pediatr       Date:  2017-08-14

4.  Incidence, Impact and Treatment of Ongoing CMV Infection in Patients with Biliary Atresia in Four European Centres.

Authors:  Björn Fischler; Piotr Czubkowski; Antal Dezsofi; Ulrika Liliemark; Piotr Socha; Ronald J Sokol; Jan F Svensson; Mark Davenport
Journal:  J Clin Med       Date:  2022-02-11       Impact factor: 4.241

5.  A Comparative Study Between Cytomegalovirus Immunoglobulin M-Positive and CMV Immunoglobulin M-Negative Biliary Atresia in Infants Attending a Tertiary Care Hospital in Bangladesh.

Authors:  Sharmin Akter; A S M Bazlul Karim; Md Wahiduzzaman Mazumder; Md Rukunuzzaman; Khan Lamia Nahid; Bishnu Pada Dey; Maimuna Sayeed; A Z M Raihanur Rahman; Kaniz Fathema; Mukesh Khadga
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2022-09-05

6.  Impact of Cytomegalovirus Infection on Short-Term Clinical Outcomes and Operative Histopathology in Infants with Biliary Atresia: A Single-Center Prospective Cohort Study.

Authors:  Gayatri Munghate; Sachit Anand; Veereshwar Bhatnagar; Sandeep Agarwala; Siddhartha Datta Gupta
Journal:  J Indian Assoc Pediatr Surg       Date:  2022-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.